Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Scand J Infect Dis ; 37(9): 637-41, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-16126562

RESUMEN

The aim of this study was to prospectively investigate 120 cases of viridans streptococcal bacteraemia (VSB) in 117 patients in major university hospitals in Slovakia in 2000-2002 (3 y) for antibacterial susceptibility, risk factors and outcome. From 127 episodes, 16 (13%) of VSB were caused by PEN-R strains and 13 (10%) by ERY-R strains. 32 cases had cancer as underlying disease (20 haematological), 41 had endocarditis and 35 were elderly (>65 y of age) patients. Concerning mortality, 29 of 127 patients died (24%). There were several risk factors associated with mortality. Solid tumour as underlying disease (p<0.02), stroke (p<0.002), concomitant lung infection (p<0.01), endoscopic procedure (p<0.036), intubation (p<0.0008), ventilatory support (p<0.002), and coma (p<0.009) were associated with more deaths. A comparison of 115 bacteraemias to 13 bacteraemias caused by erythromycin-resistant strains of Streptococcus viridans was performed. There were no significant differences in underlying disease, risk factors and mortality. Erythromycin resistance in bacteraemias caused by S. viridans did not have significant impact on outcome of the patients, nor did it show specific relation to analysed risk factors in our study. 14.5% of VSB were cause by PEN-resistant viridans streptococci. Risk factors for penicillin resistance were ventilatory support (p<0.01), intubation (p<0.001) and resistance to other antibiotics: 8 of 16 (50%) of PEN-R VSB were resistant also to erythromycin or cotrimoxazole or tetracycline compared with 9% of PEN-R VSB (p<0.005). Endoscopic procedures in the upper respiratory system were at risk for development of PEN-R VSB. There was also difference in outcome; 71% vs 22.5% (p<0.0002) of cases infected with PEN-R VSB died compared to PEN-S VSB. PEN-R is therefore clinically significant in VSB.


Asunto(s)
Antibacterianos/farmacología , Bacteriemia/microbiología , Bacteriemia/mortalidad , Farmacorresistencia Bacteriana , Estreptococos Viridans/efectos de los fármacos , Anciano , Bacteriemia/complicaciones , Preescolar , Eritromicina/farmacología , Encuestas Epidemiológicas , Humanos , Pruebas de Sensibilidad Microbiana , Resistencia a las Penicilinas , Estudios Prospectivos , Factores de Riesgo , Eslovaquia , Infecciones Estreptocócicas/complicaciones , Infecciones Estreptocócicas/microbiología , Infecciones Estreptocócicas/mortalidad , Estreptococos Viridans/aislamiento & purificación , Estreptococos Viridans/patogenicidad
4.
J Infect Chemother ; 7(1): 45-8, 2001 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11406756

RESUMEN

Amphotericin B (AmB) resistance in Candida spp. is very rare. Three cases of fungemia, due to amphotericin B-resistant Candida spp. in pediatric patients after previous neurosurgery for brain tumors, are reported. The Candida strains - one C. guillermondii, one C. lusitaniae, and one C. parapsilosis - showed minimum inhibitory concentrations (MICs) to AmB of 2-4 microg/ml. Two of the three patients had been pretreated with AmB for 5-11 days. All three patients were successfully treated with intravenous fluconazole (6-10 mg/kg per day) for 16-28 days, and all survived. Despite AmB resistance in Candida spp. being very rare, C. lusitaniae, C. guillermondii, and C. parapsilosis isolates in documented infections should be tested for AmB resistance, mainly in patients not responding to therapy with AmB.


Asunto(s)
Anfotericina B/farmacología , Antifúngicos/farmacología , Neoplasias Encefálicas/cirugía , Candida/efectos de los fármacos , Candidiasis/microbiología , Craneotomía , Infección Hospitalaria/microbiología , Fungemia/microbiología , Complicaciones Posoperatorias/microbiología , Adolescente , Anfotericina B/uso terapéutico , Antifúngicos/uso terapéutico , Neoplasias Encefálicas/complicaciones , Candida/aislamiento & purificación , Candidiasis/tratamiento farmacológico , Cateterismo Venoso Central/efectos adversos , Niño , Preescolar , Infección Hospitalaria/tratamiento farmacológico , Farmacorresistencia Microbiana , Contaminación de Equipos , Fluconazol/uso terapéutico , Fungemia/tratamiento farmacológico , Hospitales Pediátricos/estadística & datos numéricos , Humanos , Pruebas de Sensibilidad Microbiana , Complicaciones Posoperatorias/tratamiento farmacológico , Eslovaquia , Especificidad de la Especie , Derivación Ventriculoperitoneal/efectos adversos
6.
Scand J Infect Dis ; 33(12): 891-5, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11868760

RESUMEN

This study prospectively investigated all 157 cases of Acinetobacter baumannii bacteremia occurring in major university hospitals or tertiary care institutions in Slovakia during 1999 in order to determine the antimicrobial susceptibility, risk factors and outcome. Resistance to meropenem was 7.4, gentamicin 35.6, amikacin 26.5, cefepime 20.4 and ciprofloxacin 32.7%, but was only 17.3% to cefoperazone/sulbactam or ampicillin/sulbactam. Antimicrobial susceptibility of A. baumanii was lowest among isolates from cancer patients (ceftazidime 58%, piperacillin/tazobactam 52% and azthreonam 48%; p < or = 0.01-0.001). In univariate analysis, several risk factors, such as wound infection (p < or = 0.01) and ventilatory support (p < or = 0.0001), were significantly related to A. baumannii bacteremia in surgical patients. Neutropenia (p < or = 0.0001), antineoplastic chemotherapy (p < or = 0.0001) and prior antibiotic therapy (p < or = 0.0006) were significant risk factors for A. baumannii bacteremia in cancer patients. In addition, ventilatory support and surgery (p < or = 0.0001) and prior antibiotic therapy (p < or = 0.01) were significantly related to A. baumannii bacteremia in children. Colonization at other body sites (p < or = 0.05), diabetes mellitus (p < or = 0.04) and decubital ulcers/burns (p < or = 0.002) as underlying disease were significantly related to death due to A. baumannii bacteremia. In a multiple logistic regression model, decubital ulcers/burns as underlying disease (p < or = 0.0006; relative risk 5.08) and nosocomial pneumonia (p < or = 0.045; relative risk 5.08) were independent predictors of mortality. Mortality was similar between cancer and surgical patients but significantly lower in children vs. adults (p < or = 0.009).


Asunto(s)
Infecciones por Acinetobacter/etiología , Acinetobacter/efectos de los fármacos , Antibacterianos/farmacología , Acinetobacter/aislamiento & purificación , Infecciones por Acinetobacter/tratamiento farmacológico , Infecciones por Acinetobacter/mortalidad , Adulto , Antibacterianos/uso terapéutico , Niño , Infección Hospitalaria/tratamiento farmacológico , Infección Hospitalaria/epidemiología , Farmacorresistencia Bacteriana , Hospitales Universitarios , Humanos , Modelos Logísticos , Pruebas de Sensibilidad Microbiana , Neoplasias/complicaciones , Neoplasias/tratamiento farmacológico , Complicaciones Posoperatorias , Estudios Prospectivos , Factores de Riesgo , Eslovaquia/epidemiología , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA